AAV-MyoAAV 4A vector system (AAV-MyoAAV 4A expression system, AAV-MyoAAV 4A packaging plasmid system) (Amp and Kanamycin) (GeneMedi Owned)

GeneMedi (GM) AAV-MyoAAV 4A Vector system is including: 1) AAV-MyoAAV 4A Rep-Cap plasmid (AAV-MyoAAV 4A-RC plasmid) 2) AAV Helper plasmid 3) AAV expression vectors (overexpression or shRNA).

You can produce AAV-MyoAAV 4A particle in 293T cell line in high titer using GeneMedi's AAV-MyoAAV 4A Rep-Cap plasmid with GM's AAV expression vector (overexpression or shRNA) and AAV helper plasmid.

This variant, leveraging the unique properties of AAV4, could be engineered for selective targeting of muscle cells, potentially including smooth muscle tissues not efficiently targeted by other AAV serotypes. Modifications could include capsid changes for enhanced muscle cell entry or the use of regulatory elements that drive gene expression specifically in muscle tissues.

GeneMedi offers both Ampicillin (Amp) resistance and Kanamycin (Kan) resistance for the AAV Rep-Cap Plasmids, AAV expression Plasmids and AAV helper Plasmid.

Go to AAV vector system >>